Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684461 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02684461 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 20 participants.
The verdict
NCT02684461, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the effectiveness of three treatment arms that are designed to improve survival in patients with non-small cell lung cancer. Eligible subjects could be randomized to four (4) cycles of chemotherapy followed by immunotherapy, or immunotherapy followed by chemotherapy, or four cycles of chemotherapy plus immunotherapy.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2021-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684461
The ClinicalTrials.gov registry entry for NCT02684461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02684461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684461 about?
NCT02684461 is a clinical study titled "Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel". The purpose of this research study is to test the effectiveness of three treatment arms that are designed to improve survival in patients with non-small cell lung cancer. Eligible subjects could be randomized to four (4) cycles of chemotherapy followed by immunotherapy, or immunotherapy followed by ...
What is the current status of trial NCT02684461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-09-13. Estimated completion is 2021-11-19.
What interventions are being tested in trial NCT02684461?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02684461?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.